Monitor progress of next Prescription Drug User Fee Reauthorization, issues relating to US and international manufacturing, oncology issues, FDA reorganization and programs, 340B, monitoring efforts around direct-to-consumer policies.
2026 · 2nd Quarter (Apr 1 - June 30)
BEONE MEDICINES ( FORMERLY KNOWN AS BEIGENE USA, INC.)
Filed by WILLIAMS AND JENSEN, PLLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- WILLIAMS AND JENSEN, PLLC
- Filing UUID
- 665ad769-2acd-4482-9978-3c681774b4fe
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.
Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing), access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.
Monitoring efforts to onshore and build US pharmaceutical manufacturing capacity.
H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.